Measles: Resurgence and Rapid Diagnostics


Measles is a highly contagious viral disease with significant impact to public health worldwide, with cases rising sharply due to reduced vaccination rates. This reduction in routine vaccinations has resulted in susceptibility among children and adults, increasing outbreaks and complications.​

Why Are Measles Cases Rising?
Once considered largely eliminated in many regions due to widespread vaccination, measles cases saw a dramatic comeback beginning in 2022. Disruptions during the COVID-19 pandemic led to millions of children missing essential doses of the measles vaccine.1,2 Regions with high numbers of unvaccinated individuals accelerate the rapid spread of the virus,3 leading to more severe and fatal outcomes, particularly within young and immunocompromised populations.

Recognizing Measles: Classic Symptoms and Complications4,5,6

  • Symptoms start 7–14 days after exposure and typically begin with high fever (often >104°F), cough, runny nose, and watery, red eyes.
  • Koplik spots (tiny white spots inside the mouth) may appear and are very suggestive of measles before the rash develops.
  • The classic measles rash begins near the hairline and spreads downwards, often accompanied by a second fever spike.​
  • Complications include pneumonia, diarrhea, ear infections, encephalitis, and, unfortunately, death in vulnerable patients.

PCR Diagnostics
Recent surges in measles cases underscores the importance of rapid, reliable diagnostics. Modern multiplex real-time PCR has become the gold standard for laboratory confirmation due to its sensitivity, speed, and ability to quickly screen circulating strains.

BioGX’s multiplex PCR assay (BioGX REF 450-114-LMP) enables rapid screening of measles genotypes. ( A, B1*, B2, B3, C1, C2, D1*, D2, D3, D4, D5, D6, D7, D8, D9, D10, D11, E*, F*, G1*, G2, G3, H1, H2). It is designed for flexible deployment and can be validated for use with ThermoFisher-ABI QuantStudioTM Series, Bio-Rad CFX Series and BD MAXTM system.

* Strains currently not in circulation.

Diagnostics of Measles Infections
Measles, a highly contagious viral disease, requires rapid diagnosis for isolation and monitoring. A brief overview of clinical manifestations and testing approaches are defined below to highlight the importance of rapid diagnostics of suspected cases of measles. Speed of diagnosis allows for effective use of supportive care and public health interventions.

Diagnostic Strategies
Measles cases are highly contagious and spread through respiratory droplets. A majority of cases have occurred globally, with recent increases observed in regions with lower vaccination rates. Clinical manifestations include fever, cough, coryza, conjunctivitis, and a characteristic maculopapular rash. To prevent severe complications such as pneumonia, encephalitis, and death, rapid testing and isolation are crucial.

Current diagnostic tests for Measles include:

  • PCR of nasopharyngeal or throat swabs or urine
  • Serology (IgM and IgG antibodies)
  • Viral culture (less common due to turnaround time)
  • Clinical diagnosis based on characteristic symptoms and epidemiological link

References

  1. Wang, W., Wang, Q., Zhao, S., Zhou, X., Crooke, S. N., Salje, H., Jit, M., & Yu, H. (2025). COVID-19 pandemic and waning immunity disrupted measles population immunity and strategies to close immunity gaps. Nature communications, 16(1), 10966.
  2. Misin, A., Antonello, R. M., Di Bella, S., Campisciano, G., Zanotta, N., Giacobbe, D. R., Comar, M., & Luzzati, R. (2020). Measles: An Overview of a Re-Emerging Disease in Children and Immunocompromised Patients. Microorganisms, 8(2), 276.
  3. Sanyaolu, A., Okorie, C., Marinkovic, A., Ayodele, O., Abbasi, A. F., Prakash, S., … & Chan, H. (2019). Measles outbreak in unvaccinated and partially vaccinated children and adults in the United States and Canada (2018-2019): a narrative review of cases. INQUIRY: The Journal of Health Care Organization, Provision, and Financing, 56, 0046958019894098.
  4. Lucas J. (1790). An Account of Uncommon Symptoms Succeeding the Measles; with Some Additional Remarks on the Infection of Measles and Small Pox. The London medical journal, 11(Pt 4), 325–331.
  5. Gould, D. (2015). Measles: symptoms, diagnosis, management and prevention. Primary Health Care, 25(1).
  6. Battegay, R., Itin, C., & Itin, P. (2012). Dermatological signs and symptoms of measles: a prospective case series and comparison with the literature. Dermatology, 224(1), 1-4.
  7. Dunn, J. J., Baldanti, F., Puchhammer, E., Panning, M., Perez, O., & Harvala, H. (2020). Measles is back–considerations for laboratory diagnosis. Journal of Clinical Virology, 128, 104430.


Disclaimer: Information in this blog is provided for educational and informational purposes only. It is not intended to provide diagnostic or treatment recommendations. Readers are encouraged to consult appropriate scientific and public health sources.

Diagnostics of Amebic Ocular and Meningoencephalitis Infections

Rare infections of the eye and brain caused by soil and freshwater amebic parasites, namely, Acanthamoeba spp., Balamuthia mandrillaris, and Naegleria fowleri require rapid diagnosis to support targeted treatments and improved patient outcomes. BioGX has recently launched the amebic parasite multiplex for the BD MAX™ system that targets:

  • Acanthamoeba spp. (inclusive of genotypes T1-T23)
  • Balamuthia mandrillaris
  • Naegleria fowleri

A brief overview of clinical manifestations and testing approaches are defined below to highlight the importance of rapid real-time PCR diagnostics of suspected cases of keratitis, Granulomatous Amebic Encephalitis (GAE) and Primary Amebic Meningoencephalitis (PAM). Speed of diagnosis allows for effective use of anti-amoebic drugs, and support of surveillance activities.

Diagnostic Strategies

KeratitisAcanthamoeba spp. keratitis cases are associated with contact lens users. A majority of cases have occurred in North and South America, China, India, Australia and limited cases reported in Europe and Africa. Clinical manifestations include early “ring” infiltrate, pain and perineuritis.To prevent poor prognosis and irreversible blindness¹, rapid testing prevents surgery and improves patient outcomes2,3.

Current diagnostic tests for Acanthamoeba spp. Keratitis:

  • PCR of corneal scrapings or biopsy
  • In vivo confocal microscopy
  • Cultivation
  • Histopathology

Amebic MeningoencephalitisAcanthamoeba spp. infections can lead to progressive infection of the CNS (i.e., GAE) that occurs among immunocompromised/immunocompetent individuals, organ transplant recipients, and those with other comorbidities. The typical sites of infection include nasopharyngeal or cutaneous epithelium. Cases of Acanthamoeba GAE have been reported in Australia, Europe, Africa, South America, and the United States4.Clinical manifestations include confusion or other cognitive changes, fever, seizures, difficulty walking, impaired speech, vision or hearing, headache, and nausea/vomiting5,6.

Current diagnostic tests for Acanthamoeba spp. (GAE) :

  • Brain scans (CT/MRI)
  • PCR of tissue or CSF samples
  • Cultivation
  • Histopathology

Balamuthia mandrillarisBalamuthia mandrillaris infections can lead to progressive infection of the CNS (i.e., GAE) that occurs among immunocompromised/immunocompetent individuals, organ transplant recipients, and those with other comorbidities. The predominant site of infection is cutaneous epithelium. A majority of cases occur in the warmer climates of Latin America, the southwestern United States, Asia, and Australia, with limited cases reported in Europe. Clinical manifestations include confusion or other changes, fever, seizures, difficulty walking, impaired speech, vision or hearing, headache, and nausea/vomiting⁷.

Current diagnostic tests for Balamuthia mandrillaris (GAE):

  • Brain scans (CT/MRI)
  • PCR of tissue, skin, or CSF samples
  • Immunodiagnostic assays

Naegleria fowleriNaegleria fowleri is the causative agent of the invasive and fulminant, often fatal, form of meningoencephalitis referred to as Primary Amebic Meningoencephalitis (PAM). The site of infection is the olfactory neuroepithelium. Although most cases have been reported in the United States and Pakistan, infections have also occurred across Asia, Mexico, Africa, Europe, and Australasia. Clinical manifestations include headache, fever, nausea, nuchal rigidity, personality changes, seizures, coma, and behavioral abnormalities8,9.

Current diagnostic tests for Naegleria fowleri (PAM):

  • Brain scans (CT/MRI)
  • PCR of CSF samples
  • Histopathology

References

  1. Zhang Y., Xu X., et al. 2003. The global epidemiology and clinical diagnosis of Acanthamoeba keratitis. Journal of Infection and Public Health 16(6): 841-852.
  2. Li G. & Shekhawat N. 2022. Acanthamoeba epitheliopathy: Importance of early diagnosis. American Journal of Ophthalmology Case Reports 25(26): 101499.
  3. Shareef O., Shareef S., et al. 2023. New frontiers in Acanthamoeba keratitis diagnosis and management. Biology 12(12): 1489.
  4. Marciano-Cabral F., and Cabral, G. 2003. Acanthamoeba spp. as Agents of Disease in Humans. Clinical Microbiology Reviews 16(2): 273–307.
  5. Kalra S.K., Sharma P., et al. 2020. Acanthamoeba and its pathogenic role in granulomatous amebic encephalitis. Experimental Parasitology 208: 107788.
  6. Haston J.C., O’Laughlin K., et al. 2023. The epidemiology and clinical features of non-keratitis Acanthamoeba infections in the United States, 1956–2020. Open Forum Infectious Diseases, US: Oxford University Press 10(1): ofac682.
  7. Bhosale N.K. and Parija S.C. 2021. Balamuthia mandrillaris: An opportunistic, free-living ameba – An updated review. Tropical Parasitology Oct 20; 11(2): 78–88.
  8. Zhang H., Cheng X. 2021. Various brain-eating amoebae: the protozoa, the pathogenesis, and the disease. Frontiers of Medicine 15(6): 842–866.
  9. Marri A.R., Hamer D.H., et al. 2025. Naegleria fowleri and the future of surveillance: A one-health call to action. One Health 101215.


Disclaimer: Information in the blog is provided to educate and propagate general awareness and not intended to make any recommendations for diagnosis or treatment of a disease. The reader is encouraged to independently verify the accuracy of information presented in the blog.

SARS-CoV-2 August 2025 Update: BioGX Confirms Detection of Emerging NB.1.8.1, LP.8.1, XEC, XFG, XFC, JN.1 and LF.7.9 Omicron Subvariants

SARS-CoV-2

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 real-time PCR tests will continue to detect emerging variants. Specifically, variants that belong to clades NB.1.8.1, LP.8.1, XEC, XFG, XFC, JN.1 and LF.7.9.

BioGX has performed in-silico analysis of complete high coverage Omicron genomes of the following sublineages in the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV™ database as of 18 July 2025 (Table 1).

Sequence analysis of the variant genomes was compared against the SARS-CoV-2 reference genome to identify any mutations within the regions of the nucleocapsid (N-gene) targeted by BioGX products.

Based on in-silico analysis conducted on 18 July 2025, the nucleotide mutations present in NB.1.8.1, LP.8.1, XEC, XFG, XFC, JN.1 and LF.7.9 clades will not affect the detection capability of the BioGX portfolio of SARS-CoV-2 real-time PCR tests targeting the N-gene and all variants analyzed will be detected.

BioGX continues to monitor emerging SARS-CoV-2 lineage variants and any mutations with the potential to impact performance.

Table 1. Summary of SARS-CoV-2 variant (omicron sublineage) complete high coverage sequences utilized for in-silico analysis.

Omicron Sublineages Analyzed by BioGX
Omicron Sublineage Nextstrain clade Emergence Location (Date) No. Sequences Present and Analyzed
(as of 18 July 2025)
NB.1.8.1 25B Shanxi-China
(Feb 2025)		 93
LP.8.1 25A Australia
(Dec 2024)		 10
XEC 24F Spain
(July 2024)		 332
XFG 25C Japan
(May 2025)		 30
XFC Not applicable Bangladesh
(June 2025)		 2
JN.1 24A England
(Jan 2024)		 4175
LF.7.9 24H Luxembourg
(Mar 2025)		 1

Contact BioGX:

For any inquiries, please contact us by clicking this link

Learn more about pixl™ Real-time PCR Platform to improve your testing.

To order BioGX testing kits, please fill out the form here, and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/

SARS-CoV-2 Update: BioGX Confirms Detection of Emerging NB.1.8.1 Omicron Subvariants

SARS-CoV-2

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market-leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants.

BioGX has completed in silico analysis of over 977 complete high coverage Omicron genomes of sublineages belonging to the NB.1.8.1 clade present in the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV™ database as of 02 June 2025.

Sequence analysis of the variant genomes was compared against the SARS-CoV-2 reference genome to identify any mutations within the regions of the nucleocapsid (N-gene) targeted by BioGX products.

Based on in-silico analysis 02 June 2025, the nucleotide mutations present in NB.1.8.1 clade will not affect the detection capability of the BioGX portfolio of SARS-CoV-2 products, and all variants analyzed will be detected.

BioGX continues to monitor emerging SARS-CoV-2 lineage variants and any mutations with the potential to impact performance.

Contact BioGX:

For any inquiries, please contact us by clicking this link

Learn more about pixl™ Real-time PCR Platform to improve your testing.

To order BioGX testing kits, please fill out the form here, and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/

Molecular Testing with PCR: The Gold Standard for Rapid & Accurate Diagnosis

The world of diagnostic testing has been revolutionized by the advent of molecular techniques. Among these, the polymerase chain reaction (PCR) has emerged as the most powerful and reliable method. PCR testing has not only transformed the way we diagnose diseases but also set a benchmark for precision and speed in the field of molecular diagnostics. Let’s explore the brilliance of PCR, its numerous applications, and how it continues to shape the modern diagnostic landscape.

Overview of PCR – How It Works and Why It’s Crucial in Molecular Testing
At its core, PCR is a molecular technique designed to amplify and detect specific DNA sequences. Think of it as a molecular photocopier that takes a tiny fragment of genetic material and replicates it exponentially, allowing scientists and clinicians to detect even the smallest traces of pathogens or genetic abnormalities.

Here’s how PCR works
PCR operates through a series of thermal cycles that include:

  • 1. Denaturation – The DNA sample is heated to around 94-98°C, causing the double-stranded DNA to separate into two single strands.
  • 2. Annealing – The temperature is lowered to 50-65°C, allowing short DNA primers to bind to the target sequences.
  • 3. Extension – A heat-stable DNA polymerase (such as Taq polymerase) extends the primers by adding nucleotides, creating new DNA strands.
  • 4. Repetition – This cycle is repeated multiple times, exponentially amplifying the DNA for detection and analysis.

Why PCR is Crucial in Molecular Testing
PCR’s strength lies in its precision, sensitivity, and adaptability. It can detect the presence of infectious agents, genetic mutations, and other biomarkers with unparalleled accuracy. In a world where early and accurate diagnosis can mean the difference between life and death, PCR stands as the gold standard.

Common Applications of PCRPCR’s versatility has made it a cornerstone in various fields of diagnostics:

1. Infectious Disease Diagnostics
PCR has become the backbone of infectious disease testing. Unlike traditional culture methods, which can take days, PCR delivers results in a matter of hours. It is extensively used to diagnose diseases such as:

  • COVID-19 – PCR was the gold standard for detecting SARS-CoV-2 due to its high sensitivity and specificity.
  • Influenza – PCR testing helps differentiate between strains of flu viruses for appropriate treatment.
  • Tuberculosis (TB) – PCR is used to detect Mycobacterium tuberculosis directly from sputum samples, improving diagnosis speed.
  • Sexually Transmitted Infections (STIs) – PCR is employed in the detection of chlamydia, gonorrhea, and human papillomavirus (HPV).

2. Genetic Testing
Genetic disorders and inherited conditions can be identified through PCR by detecting specific genetic mutations. From prenatal genetic screening to cancer genomics, PCR continues to illuminate the underlying causes of various conditions.

  • Newborn Screening – Identifies genetic disorders like cystic fibrosis and sickle cell anemia early in life.
  • Cancer Genomics – Detects mutations in genes associated with cancers, aiding in personalized treatment.
  • Carrier Screening – Determines whether a person carries a gene for inherited diseases such as Tay-Sachs or Huntington’s disease.

3. Forensic Science and Paternity Testing
Outside the clinical realm, PCR has made its mark in forensic science, where it helps identify suspects and analyze crime scene evidence. It is also an essential tool in research laboratories for cloning, gene expression studies, and more.

4. Environmental and Food Safety Testing
PCR is also used to detect contaminants, pathogens, or genetically modified organisms (GMOs) in food products and environmental samples, ensuring safety and compliance with regulations.

Benefits of PCR – High Sensitivity, Specificity, and Rapid Turnaround Times
The benefits of PCR are as remarkable as its capabilities. Here’s why it is often referred to as the gold standard:

1. High Sensitivity and Specificity
PCR can detect even minute quantities of genetic material, making it highly reliable for diagnosing diseases at early stages. Unlike serological tests that rely on the presence of antibodies (which take time to develop), PCR identifies the pathogen’s genetic material directly, leading to a more accurate diagnosis.

2. Targeted Accuracy/strong>
By targeting unique DNA sequences, PCR ensures accurate identification of the pathogen or mutation in question, minimizing false positives.

3. Rapid Turnaround Times
Traditional diagnostic techniques often require days or weeks to produce results. PCR, on the other hand, can provide answers within hours, enabling timely interventions and treatment.

  • Pandemic Response – During COVID-19, PCR testing played a crucial role in controlling virus spread through quick and accurate identification of infected individuals.
  • Hospital Settings – PCR aids in the rapid diagnosis of life-threatening infections such as sepsis, enabling prompt treatment.

4. Versatility
PCR can be adapted for various applications, including:

  • Detecting RNA viruses using reverse transcription PCR (RT-PCR).
  • Quantifying DNA using real-time PCR (qPCR).
  • Identifying multiple pathogens simultaneously with multiplex PCR.

5. Automation and Scalability
With advances in PCR technology, automation has significantly increased testing efficiency. High-throughput PCR systems enable mass testing, making them indispensable in clinical laboratories and public health initiatives.

BioGX’s Role – How BioGX Solutions Fit into the Modern PCR Testing Landscape
In the evolving world of molecular diagnostics, companies like BioGX have taken PCR to new heights by offering innovative solutions that streamline and enhance molecular testing processes. BioGX has emerged as a leading innovator in PCR-based molecular diagnostics, providing cutting-edge solutions tailored for modern healthcare needs. The company specializes in developing real-time PCR reagents that streamline molecular testing workflows across diverse sectors.

1. Simplifying PCR Testing with Ready-to-Use Reagents
BioGX offers pre-mixed, lyophilized PCR reagents that eliminate the need for complex reagent preparation. These user-friendly solutions:

  • Reduce human error.
  • Minimize contamination risks.
  • Enhance consistency and reproducibility in test results.

2. Wide Range of PCR Reagents
BioGX provides PCR-based solutions for detecting infectious pathogens, genetic mutations, and food safety hazards. Their reagents support:

  • COVID-19 and respiratory virus panels.
  • Sexually transmitted infection (STI) testing.
  • Urinary tract infection testing.
  • Antimicrobial testing.

3. Compatibility with Open PCR Platforms
BioGX’s PCR reagents are designed to be compatible with various PCR instruments, ensuring flexibility and ease of integration into existing laboratory workflows.

4. Point-of-Care and Decentralized Testing
BioGX is at the forefront of making PCR testing accessible outside of centralized labs. Their innovative PCR solutions enable:

  • Rapid testing at hospitals, clinics, and mobile labs.
  • Faster patient diagnosis and treatment decisions.

5. Commitment to Quality and Regulatory Compliance
BioGX adheres to strict quality standards, ensuring that their PCR assays meet ISO13485 and other global regulatory requirements. This commitment to quality makes their solutions reliable for molecular diagnostics worldwide.

PCR has revolutionized molecular diagnostics, establishing itself as the gold standard for rapid and accurate disease detection. Its unmatched sensitivity, specificity, and versatility make it indispensable across medical, forensic, and environmental testing fields. With companies like BioGX pushing the boundaries of innovation, PCR technology continues to evolve, making molecular testing more efficient, accessible, and impactful in global healthcare.

As the demand for precise and rapid diagnostics grows, PCR remains the cornerstone of molecular testing, helping save lives through early and accurate disease detection. Whether in hospitals, research labs, or point-of-care settings, PCR’s impact on healthcare is undeniable.

Contact BioGX:

For any inquiries, please contact us by clicking this link

To order BioGX testing kits, please fill out the form here, and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/

Learn More


Disclaimer: Information in the blog is provided to educate and propagate general awareness and is not intended to make any recommendations for diagnosis or treatment of a disease. The reader is encouraged to independently verify the accuracy of the information presented in the blog.

A Comprehensive Guide to UTI Diagnosis: Employing BioGX’s Multiplex PCR Technology for fast and accurate Testing

Urinary tract infections (UTIs) are one of the most common infections, affecting millions worldwide every year. Timely and accurate diagnosis is essential to prevent complications and ensure effective treatment. BioGX, a leader in molecular diagnostic solutions, offers multiplex qPCR assays designed to simplify and improve the detection of UTI pathogens. This comprehensive guide explores how UTIs are diagnosed and how BioGX’s innovative multiplex technology is changing the game for healthcare providers.

What is Urinary Tract Infection (UTI)?
A urinary tract infection occurs when bacteria enter and multiply within the urinary system, which includes the kidneys, bladder, ureters, and urethra. While UTIs can affect any part of the urinary tract, most infections are typically found in the bladder and urethra. Common symptoms include:

  • Pain or burning during urination
  • Frequent urge to urinate
  • Cloudy or strong-smelling urine
  • Pelvic pain in women

If left untreated, a UTI can spread to the kidneys, potentially causing severe complications. Rapid and accurate diagnosis is critical to prevent such outcomes.

Traditional UTI Diagnostic Methods
UTI diagnosis has traditionally involved several methods, which include:

1. Urine Culture Testing:
 Urine culture is the gold standard for diagnosing UTIs. A urine sample is incubated in a lab to detect bacterial growth, which typically takes 24–48 hours. Although accurate, this method requires a waiting period, which can delay treatmen

2. Urine Dipstick Test:
A urine dipstick test provides quick results by detecting the presence of white blood cells, nitrites, and proteins in the urine, which may indicate an infection. However, dipstick tests are less accurate than urine cultures and may produce false positives or false negatives.

3. Microscopic Urine Analysis:
Microscopic analysis involves examining a urine sample under a microscope to identify bacteria, white blood cells, and other indicators of infection. While faster than culture tests, it lacks the specificity needed for accurate diagnosis. While these traditional methods are useful, they often come with limitations like wait times, sensitivity issues, and the need for specialized lab facilities. This is where BioGX’s multiplex PCR technology provides a more efficient solution.

Introducing BioGX’s Multiplex Technology for UTI detection
BioGX has developed a comprehensive multiplex PCR panels that allows clinical laboratories to detect multiple targets (such as specific bacteria or resistance genes) simultaneously, ensuring faster and more accurate results. This technology is particularly effective for diagnosing UTIs, as it enables the detection of various bacterial strains associated with urinary tract infections. How BioGX’s Multiplex Technology Works BioGX’s multiplex PCR technology is based on molecular diagnostics that target bacterial DNA. By leveraging real-time PCR (polymerase chain reaction), it can rapidly amplify and detect multiple bacterial strains within a single sample. Here’s a breakdown of how the process works:

1. Sample Collection and Preparation:
 A urine sample is collected from the patient, similar to traditional methods. The sample is then prepared for testing, with DNA extracted from any bacteria present in the sample. This step is crucial as it ensures that only bacterial DNA is targeted, minimizing the chances of contamination.

2. Multiplex Real-Time PCR Amplification:
Once the DNA is isolated, the real-time PCR process begins. PCR works by amplifying specific DNA sequences associated with common UTI pathogens, such as Escherichia coli, Klebsiella pneumoniae, and Staphylococcus saprophyticus. BioGX’s technology allows for simultaneous amplification of multiple bacterial DNA sequences, reducing testing time.

3. Detection of Pathogens and Resistance Genes
BioGX’s multiplex technology also detects antimicrobial resistance genes, which are markers of bacterial resistance to specific antibiotics. This feature is vital for clinicians, as it enables them to select the most effective antibiotic treatment based on the resistance profile of the bacteria.

4. Real-Time Results and Analysis
As the DNA is amplified, the system detects specific fluorescence signals, each corresponding to a different pathogen or resistance gene. These signals allow healthcare providers to identify the bacterial strains present and their resistance status in real-time, providing results in a matter of hours rather than days.

Advantages of BioGX’s Multiplex Technology in UTI Detection
BioGX’s multiplex technology offers several key advantages over traditional diagnostic methods, making it a highly effective solution for UTI detection.

1. Speed and Efficiency
Unlike urine culture, which requires at least 24–48 hours for results, BioGX’s multiplex technology can deliver diagnostic insights within a few hours. This speed allows healthcare providers to make timely treatment decisions, improving patient outcomes.

2. Comprehensive Pathogen Detection
Traditional UTI tests often target a limited number of bacteria, potentially missing less common pathogens. BioGX’s multiplex technology, however, is designed to identify multiple bacterial species simultaneously. This comprehensive detection reduces the risk of missed infections, especially in complex or recurrent UTI cases.

3. Antimicrobial Resistance Profiling
One of the standout features of BioGX’s technology is its ability to identify antibiotic resistance genes. By determining which antibiotics a bacterial strain is resistant to, healthcare providers can avoid prescribing ineffective treatments, which helps reduce the spread of antimicrobial resistance.

4. Minimal Sample Requirement
With BioGX’s multiplex technology, only a small urine sample is required, making it an ideal option for settings where sample collection may be challenging. This minimal sample requirement also enhances patient comfort and streamlines the testing process.

Applications of BioGX’s Multiplex Technology in Clinical Settings
BioGX’s multiplex technology is particularly useful in various clinical scenarios, providing healthcare professionals with the flexibility they need to diagnose and treat UTIs effectively.

1. Emergency Room Settings:
 UTIs are a common reason for emergency room visits, especially among elderly patients. The rapid diagnostic capabilities of BioGX’s multiplex technology enable ER staff to diagnose infections and administer treatment in a single visit, improving patient care and reducing wait times.

2. Outpatient Clinics:
For outpatient clinics and urgent care centers, BioGX’s solution provides a fast and accurate method to diagnose UTIs without sending samples to a central lab. This quick turnaround time ensures that patients receive the appropriate treatment immediately.

3. Long-Term Care Facilities:
UTIs are a prevalent issue in nursing homes and long-term care facilities, where delays in diagnosis can lead to severe health complications. BioGX’s multiplex technology provides these facilities with a practical solution for on-site testing, allowing caregivers to detect and treat infections promptly.

How BioGX’s Multiplex Technology Supports Antibiotic Stewardship
Antibiotic stewardship is the responsible use of antibiotics to minimize resistance. BioGX’s technology supports this initiative by:

  • Identifying resistance genes, enabling targeted treatment
  • Reducing the overuse of broad-spectrum antibiotics
  • Providing rapid results, which minimizes unnecessary antibiotic prescriptions

By helping healthcare providers prescribe effective, targeted antibiotics, BioGX’s multiplex technology contributes significantly to global antibiotic stewardship efforts.

The Future of UTI Pathogen Detection with BioGX’s Multiplex Technology
BioGX is continuously refining its multiplex technology to meet the evolving needs of healthcare providers. Future developments may include expanded pathogen panels, enhanced resistance gene detection, and even faster testing processes. As molecular diagnostics advance, BioGX aims to stay at the forefront of innovation, empowering healthcare providers with the tools they need to combat UTIs and other infections effectively.

Conclusion: BioGX’s Multiplex PCR Technology – A Game Changer in UTI Pathogen Detection

BioGX’s multiplex technology offers a powerful solution for detecting pathogens with speed, accuracy, and precision. Its ability to detect multiple pathogens and resistance genes within a single assay streamlines and simplifies the laboratory workflows. For laboratories validating and adopting BioGX’s innovative multiplex technology means enabling faster treatment decisions, improved patient outcomes, and a stronger commitment to antibiotic stewardship. In the face of growing antibiotic resistance and rising UTI cases, BioGX’s technology adoption by clinical laboratories is helping shape a healthier future for all.

Contact BioGX:

For any inquiries, please contact us by clicking this link

To order BioGX testing kits, please fill out the form here and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/

Learn More


Disclaimer: Information in the blog is provided to educate and propagate general awareness and not intended to make any recommendations for diagnosis or treatment of a disease. The reader is encouraged to independently verify the accuracy of information presented in the blog.

Understanding the Recent Resurgence of Mpox: Challenges, Implications, and the Path Forward

The global health community has once again turned its attention to Mpox (formerly known as Monkeypox) as reports of new outbreaks have emerged in various regions. The recent resurgence of Mpox is a stark reminder that zoonotic diseases, which jump from animals to humans, remain a significant challenge to global public health. BioGX, as a leader in molecular diagnostics, is committed to providing the tools and knowledge necessary to combat these emerging threats. This blog explores the challenges posed by the resurgence of Mpox, its broader implications, and the strategies we must employ moving forward.

The Challenges of Mpox Resurgence

1. Emerging Variants and Transmission Patterns:
One of the primary challenges in addressing the resurgence of Mpox is the emergence of new variants that may have altered transmission dynamics. While Mpox was previously considered a relatively rare disease with limited human-to-human transmission, recent outbreaks have shown a concerning increase in cases, particularly in densely populated urban areas. This shift suggests changes in the virus’s behavior, possibly due to mutations that enhance its transmissibility or ability to evade the immune system.

2. Limited Awareness and Diagnostic Infrastructure:
 Despite the global response to the COVID-19 pandemic, which heightened awareness of infectious diseases, Mpox remains underrecognized in many regions. Limited awareness among healthcare providers and the general public can lead to delayed diagnosis and treatment, exacerbating the spread of the disease. Moreover, many regions lack the diagnostic infrastructure required for rapid and accurate detection of Mpox, hindering timely interventions.

3. Public Health Response and Resource Allocation:
The global response to emerging infectious diseases is often hampered by competing priorities and limited resources. As the world continues to grapple with the long-term impacts of COVID-19, public health systems may be stretched thin, making it challenging to allocate adequate resources to combat the resurgence of Mpox. Ensuring a swift and coordinated response is crucial to preventing the disease from gaining a foothold in vulnerable populations.

Broader Implications of the Resurgence

1. Impact on Global Health Security:
The resurgence of Mpox serves as a stark reminder of the interconnectedness of global health. Zoonotic diseases like Mpox do not respect borders, and their spread can have far-reaching consequences for global health security. The ongoing outbreaks underscore the need for a robust and coordinated international response to emerging infectious diseases, with a focus on early detection, rapid response, and cross-border collaboration.

2. The Role of Diagnostics in Containing Outbreaks:
 Accurate and timely diagnostics are at the heart of any effective outbreak response. As a leading manufacturer of molecular diagnostics, BioGX plays a crucial role in providing the tools necessary to detect Mpox at its earliest stages. Our Monkeypox PCR Assay, designed for precise and reliable detection, is an essential component of the global effort to contain the spread of the virus. By enabling early identification of cases, our assays empower healthcare providers to take swift action, reducing the risk of widespread transmission.

3. Lessons Learned and the Path Forward:
The resurgence of Mpox offers valuable lessons for the global health community. It highlights the importance of continuous surveillance, investment in diagnostic infrastructure, and the need for public health preparedness. As we navigate this resurgence, it is essential to apply the lessons learned from past outbreaks, including the COVID-19 pandemic, to strengthen our response strategies.

The Path Forward: BioGX’s Commitment to Global Health

At BioGX, we are committed to supporting global health initiatives by providing innovative diagnostic solutions that address the challenges of emerging infectious diseases. Our Monkeypox PCR Assay is a testament to our dedication to improving public health outcomes through reliable and accessible diagnostics. As the situation continues to evolve, BioGX will remain at the forefront, collaborating with healthcare providers, researchers, and public health authorities to ensure that we are equipped to meet the challenges of Mpox head-on.

Key Takeaways for Healthcare Providers:

  • Stay Informed: Keep up to date with the latest information on Mpox transmission, symptoms, and treatment options.
  • Utilize Reliable Diagnostics: Leverage advanced diagnostic tools like the BioGX Monkeypox PCR Assay for early detection and confirmation of cases.
  • Collaborate and Communicate: Work closely with local and international health authorities to share information, resources, and best practices for managing Mpox outbreaks.

Conclusion:

The recent resurgence of Mpox is a call to action for the global health community. By understanding the challenges, recognizing the implications, and taking decisive steps forward, we can mitigate the impact of this zoonotic disease. At BioGX, we are proud to contribute to this effort, providing the diagnostic solutions necessary to safeguard public health and prevent the spread of Mpox. Together, we can navigate this resurgence and build a more resilient global health system.

Contact BioGX:

For any inquiries, please contact us by clicking this link

To order BioGX testing kits, please fill out the form here and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/

Learn More


Disclaimer: Information in the blog is provided to educate and propagate general awareness and not intended to make any recommendations for diagnosis or treatment of a disease. The reader is encouraged to independently verify the accuracy of information presented in the blog.

August 2024 Update: BioGX in silico analysis of SARS-CoV-2 variants of interest and emerging variants

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants.

BioGX has completed in silico analysis of over 290,000 complete high coverage Omicron genomes of sublineages belonging to the JN.1, EG.5, BA.2.86, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, and JG.3 clades present in the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV™ database as of 31 December, 2023.

Sequence analysis of the variant genomes was compared against the SARS-CoV-2 reference genome to identify any mutations within the regions of the nucleocapsid (N-gene), membrane (M-gene), and the coding region of the ORF1a gene (RdRp) targeted by BioGX products.

Based on in-silico analysis on 07th August 2024 and empirical testing, the nucleotide mutations present in JN.1, EG.5, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, JG.3, BA.2.86 and the BA.2.86 sublineages KP.3.1.1, KP.3, LB.1, KP.2.3 and KP.2 will not affect the detection capability of the BioGX portfolio of SARS-CoV-2 products and all variants analyzed will be detected.

BioGX continues to monitor emerging SARS-CoV-2 lineage variants and any mutations with the potential to impact performance.

Omicron Sublineages Analyzed by BioGX
Omicron sublineage Nextstrain clade Emergence Location (Date) No. Sequences Present and Analyzed

(as of 31DEC2023)
JN.1 23I Luxembourg / Iceland (AUG 2023) 15,548
EG.5 23D Denmark
(JUL 2023)		 1795
BA.2.86 21L Denmark
(JUL 2023)		 416
XBB.1.5 23A USA (OCT 2022) 172,673
XBB.1.16 23B USA (JAN 2023) 33,318
HV.1 23F China (JAN 2023) 30,422
HK.3 23H USA (OCT 2022) 22,572
JD.1.1 23A USA (JUL 2023) 7,601
JG.3 23F France (JUL2023) 8,370

December 2023 Update: BioGX in silico analysis of SARS-CoV-2 variants of interest and emerging variants

BioGX continuously monitors the evolution of SARS-CoV-2 variants to ensure our market leading SARS-CoV-2 RT-PCR tests will continue to detect emerging variants.

BioGX has completed in silico analysis of over 290,000 complete high coverage Omicron genomes of sublineages belonging to the JN.1, EG.5, BA.2.86, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, and JG.3 clades present in the Global Initiative on Sharing Avian Influenza Data (GISAID) EpiCoV™ database as of 31 December, 2023 (Table 1). Sequence analysis of the variant genomes was compared against the SARS-CoV-2 reference genome to identify any mutations within the regions of the nucleocapsid (N-gene), membrane (M-gene), and the coding region of the ORF1a gene (RdRp) targeted by BioGX products.

Based on in silico analysis and empirical testing, the nucleotide mutations present in the JN.1, EG.5, BA.2.86, XBB.1.5, XBB.1.16, HV.1, HK.3, JD.1.1, and JG.3 clades at the time of this analysis will not affect the detection capability of the BioGX portfolio of SARS-CoV-2 products and all variants analyzed will be detected.

BioGX continues to monitor emerging SARS-CoV-2 lineage variants and any mutations with the potential to impact performance.

Table 1. Number of sequences analyzed for each Omicron sublineage available from GISAID as of 31 December 2023.

Omicron Sublineages Analyzed by BioGX
Omicron sublineage Nextstrain clade Emergence Location (Date) No. Sequences Present and Analyzed

(as of 31DEC2023)
JN.1 23I Luxembourg / Iceland (AUG 2023) 15,548
EG.5 23D Denmark
(JUL 2023)		 1795
BA.2.86 21L Denmark
(JUL 2023)		 416
XBB.1.5 23A USA (OCT 2022) 172,673
XBB.1.16 23B USA (JAN 2023) 33,318
HV.1 23F China (JAN 2023) 30,422
HK.3 23H USA (OCT 2022) 22,572
JD.1.1 23A USA (JUL 2023) 7,601
JG.3 23F France (JUL2023) 8,370

Enhancing UTI Detection with PCR Reagents

Introduction:

Urinary tract infections (UTIs) are among the most common bacterial infections, affecting millions of individuals worldwide each year. Prompt and accurate diagnosis is essential for guiding appropriate treatment and preventing complications. In recent years, PCR (polymerase chain reaction) reagents have emerged as valuable tools in the diagnosis of UTIs, offering advantages in sensitivity, specificity, and speed compared to traditional microbiology methods. In this article, we’ll explore how PCR reagents are revolutionizing UTI testing and improving patient care.

1. Understanding PCR Reagents in UTI Testing:

PCR reagents are essential components used to amplify and detect specific DNA sequences in clinical samples, such as urine.
– In UTI testing, PCR reagents target genetic markers unique to common uropathogens, such as Escherichia coli, Klebsiella pneumoniae, and Enterococcus faecalis.

– By amplifying and detecting genetic markers specific to these pathogens, PCR assays can rapidly and accurately identify their presence in urine samples, even at low cell counts which are hard to grow and detect by traditional culture methods.

2. Advantages of PCR Reagents in UTI Diagnosis:

Sensitivity: PCR assays using high-fidelity DNA polymerases can detect bacterial DNA with exceptional sensitivity, enabling the diagnosis of UTIs even in cases with low bacterial loads.
Specificity: PCR assays can distinguish between different bacterial species and strains, providing clinicians with valuable information for targeted antibiotic therapy.
Speed: PCR assays offer rapid turnaround times, with results typically available within a few hours, allowing for prompt initiation of appropriate treatment.
Automation: PCR assays can be automated, allowing for high-throughput testing in clinical laboratories, reducing manual labor and increasing efficiency.

3. Applications of PCR Reagents in UTI Testing:

Detection of Uropathogens: PCR assays targeting specific bacterial genes, such as those encoding virulence factors or antibiotic resistance determinants, can identify uropathogens and provide additional information for treatment decisions.
Antimicrobial Susceptibility Testing:Antimicrobial Susceptibility Testing: PCR-based methods can detect genetic markers associated with antimicrobial resistance, guiding the selection of appropriate antibiotics and helping to combat the rise of antibiotic resistance in UTIs.
Syndromic Panels:Multiplex PCR assays can simultaneously detect multiple uropathogens and differentiate between bacterial and viral causes of UTIs, offering comprehensive diagnostic information in a single test.

4. Challenges and Considerations:

Standardization: Ensuring the accuracy and reliability of PCR assays requires standardization of protocols, quality control measures, and validation studies.

Cost:While PCR assays may offer advantages in sensitivity and speed, they may be more costly than traditional culture-based methods, necessitating careful consideration of cost-effectiveness.

The Challenge of UTI Diagnosis

Traditional methods of UTI diagnosis, such as urine culture and microscopy, have limitations in terms of sensitivity, specificity, and turnaround time. These methods often require prolonged incubation periods and may miss low-level bacterial infections, leading to delayed treatment and potential complications. Moreover, distinguishing between symptomatic infection and asymptomatic bacteriuria can be challenging, particularly in certain patient populations.

In contrast, PCR technology offers a rapid and highly sensitive alternative to traditional UTI diagnostic methods. By targeting specific bacterial DNA sequences present in urine samples, PCR can detect the presence of UTI-causing pathogens with unparalleled accuracy. PCR reagents, which contain all the necessary components for PCR amplification and detection, play a crucial role in facilitating this process.

PCR Reagents: A Cornerstone of Molecular UTI Testing

BioGX custom-manufactured PCR reagents offer a comprehensive solution for the rapid and accurate detection of bacterial pathogens present in urine samples. Packaged in a single tube format, BioGX’s PCR reagents* streamline the testing process, minimize hands-on time and simplify workflow for laboratories. By combining all necessary components for PCR amplification and detection into a single lyophilized mastermix, BioGX ensures laboratories can achieve consistent and reliable performance, during their validation studies and routine testing.

Advantages of BioGX’s PCR Reagents for UTI Testing:

1. High Sensitivity:
BioGX’s PCR reagents* are optimized to detect low levels of bacterial DNA, even in cases of low bacterial load, ensuring reliable detection of UTI pathogens from urine samples.

2. Specificity: With carefully designed primer sets targeting conserved regions of bacterial genomes, BioGX’s PCR reagents* offer exceptional specificity, minimizing the risk of false-positive results and ensuring accurate detection.

3. Rapid Turnaround Time: By leveraging the speed and efficiency of PCR technology, BioGX’s PCR reagents* provide results within hours, enabling timely initiation of targeted antibiotic therapy and improving patient outcomes.

4. User-Friendly FormatPackaged in a single lyophilized tube format, BioGX’s PCR reagents* are easy to use, requiring minimal hands-on manipulation and reducing the risk of contamination, thereby enhancing laboratory efficiency and productivity.

Conclusion:

PCR reagents have transformed the landscape of UTI testing, offering unparalleled sensitivity, specificity, and speed compared to traditional methods. By harnessing the power of PCR technology, clinicians can diagnose UTIs with greater precision, guide targeted antibiotic therapy, and improve patient outcomes. As PCR assays continue to evolve and become more accessible, they hold tremendous promise for enhancing the diagnosis and management of UTIs, ultimately benefiting patients and healthcare systems alike.

Contact BioGX:

For any inquiries, please contact us by clicking this link

To order BioGX testing kits, please fill out the form here and a product specialist will reach out to you. visit https://biogx.com/request-a-quote/

Learn More


*Custom manufactured as per customer specified requirements

Disclaimer: Information in the blog is provided to educate and propagate general awareness and not intended to make any recommendations for diagnosis or treatment of a disease. The reader is encouraged to independently verify the accuracy of information presented in the blog.